Prism Medico & Pharmacy Ltd
Incorporated in 1985, Prism Medico and Pharmacy Ltd is in the business of Wholesale and Retail of straw, fodder and other animal/ poultry feed[1]
- Market Cap ₹ 15.6 Cr.
- Current Price ₹ 25.7
- High / Low ₹ 39.2 / 19.1
- Stock P/E
- Book Value ₹ 21.7
- Dividend Yield 0.00 %
- ROCE 1.65 %
- ROE 1.09 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.18 times its book value
- Debtor days have improved from 35.1 to 21.0 days.
- Company's working capital requirements have reduced from 117 days to 29.7 days
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 25.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | TTM | |
|---|---|---|---|---|
| 5.27 | 22.78 | 54.43 | 41.89 | |
| 5.21 | 21.95 | 54.10 | 42.07 | |
| Operating Profit | 0.06 | 0.83 | 0.33 | -0.18 |
| OPM % | 1.14% | 3.64% | 0.61% | -0.43% |
| 0.07 | -0.03 | 0.07 | 0.08 | |
| Interest | 0.14 | 0.29 | 0.11 | 0.18 |
| Depreciation | 0.21 | 0.45 | 0.38 | 0.33 |
| Profit before tax | -0.22 | 0.06 | -0.09 | -0.61 |
| Tax % | 4.55% | 116.67% | -144.44% | |
| -0.22 | 0.00 | 0.04 | -0.55 | |
| EPS in Rs | -0.36 | 0.00 | 0.07 | -0.91 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -245% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 1% |
| 3 Years: | 57% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Sep 2019 | |
|---|---|---|---|---|
| Equity Capital | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves | 6.81 | 6.81 | 6.85 | 7.10 |
| 3.50 | 2.18 | 2.27 | 0.00 | |
| 0.89 | 0.75 | 6.03 | 11.73 | |
| Total Liabilities | 17.26 | 15.80 | 21.21 | 24.89 |
| 9.91 | 9.31 | 8.91 | 8.94 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 2.61 | 1.36 | 1.36 |
| 7.35 | 3.88 | 10.94 | 14.59 | |
| Total Assets | 17.26 | 15.80 | 21.21 | 24.89 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| 0.00 | 3.55 | -0.44 | |
| 0.00 | -2.53 | 0.00 | |
| 0.00 | -1.61 | -0.50 | |
| Net Cash Flow | 0.00 | -0.59 | -0.95 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| Debtor Days | 49.17 | 0.00 | 20.99 |
| Inventory Days | 301.37 | 25.56 | 9.53 |
| Days Payable | 67.17 | 9.26 | 39.36 |
| Cash Conversion Cycle | 283.38 | 16.29 | -8.84 |
| Working Capital Days | 292.28 | 29.16 | 29.71 |
| ROCE % | 2.67% | 1.65% |
Documents
Announcements
-
Details Of Related Party Transactions (RPT'S) As Per Regulation 23(9) Of SEBI (LODR) Regulations, 2015.
14 Nov - Disclosure of related party transactions for H1 2024.
-
Intimation As Per Regulation 6(1) And Regulation 30 Read With Clause 7 Of Para A Of Schedule III Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
14 Nov - Resignation of Mr. Vishwambhar Dayal Gupta from directorship.
-
Board Meeting Outcome for Outcome Of The Board Meeting - Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
14 Nov - Approved financial results and accepted director's resignation.
-
Board Meeting Intimation for Regulation 29(1) Of SEBI (LODR) Regulations, 2015.
7 Nov - Board meeting to approve financial results for Q2 2024.
-
Undertaking Of Functional Website.
21 Oct - Dear Sir/Madam, Please find the attached undertaking for functional website. Thanking You.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Alteration in MoA:[1]
In FY22, company altered its main objects of Memorandum of Association and inserted new objects viz.:
a) To manufacture, import, export, wholesale or retail trade all kinds of pharmaceuticals, antibiotics, drugs, medicines, biological, Nutraceutical, healthcare, Ayurveda and dietary supplement products, medicinal preparations, vaccines, chemicals, chemical products, dry salters, mineral waters, wines, cordials, liquors, soups, broths and other restoratives or foods
b) To deal in medicinal goods viz. surgical instruments, contraceptives, photographic goods, oils, perfumes, cosmetics, patent medicines, soaps, artificial limbs, hospital requisites, proprietary medicines, veterinary medicines and tinctures extracts
c) To carry on the business of vialling, bottling, repacking, processing of tablets, capsules, syrups, injections, ointments, etc.
d) To carry on the business of chemists, druggists, buyers, sellers, agents, distributors and stockiest of all kinds of pharmaceuticals and allied products